Who Paid My Doc
Vyxeos
Drug Hematology/Oncology
NDC 68727-745-02
General payments
$1,578,205
Research payments
$46,450,458
Through program year 2025, $1,578,205 in general payments and $46,450,458 in research payments were reported against Vyxeos (Hematology/Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $33,300 | 24 |
| 2025 | Research | $1,435,855 | 72 |
| 2024 | General | $605,797 | 368 |
| 2024 | Research | $3,809,353 | 368 |
| 2023 | General | $400,530 | 601 |
| 2023 | Research | $1,673,521 | 238 |
| 2022 | General | $538,456 | 2,232 |
| 2022 | Research | $39,531,728 | 457 |
| 2021 | General | $123 | 7 |
Breakdown
The top 5 of 15 recipients; each share is of general payments naming this product in 2025.
The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 10 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
3,232 general · 1,135 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.